Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 12, 2021Blood Cancer JournalOpen Access

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJoseph MıkhaelTranslational Genomics Research InstituteKBKarim Belhadj‐MerzougCentre Hospitalier Universitaire Henri-MondorCHCyrille HulinSciences Po Bordeaux

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mıkhael et al. (2021) studied this question.

synapsesocial.com/papers/6a6b968f47a1bfb288f330b1https://doi.org/10.1038/s41408-021-00478-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients2019 · 92 citations
  2. 2Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab792014 · 226 citations
  3. 3SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies2014 · 335 citations
  4. 4Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma2020 · 25 citations
  5. 5A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma2020 · 54 citations